<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="462">
  <stage>Registered</stage>
  <submitdate>22/07/2004</submitdate>
  <approvaldate>22/07/2004</approvaldate>
  <nctid>NCT00088205</nctid>
  <trial_identification>
    <studytitle>Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma</studytitle>
    <scientifictitle>A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H6Q-MC-JCAO</secondaryid>
    <secondaryid>8360</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mantle-Cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - enzastaurin

Experimental: A - 


Treatment: drugs: enzastaurin
500 mg, oral, daily, up to six 28 day cycles

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To estimate the rate of freedom from progression for at least 3 cycles in patients with relapsed mantle cell lymphoma who have received enzastaurin.</outcome>
      <timepoint>baseline, after 3 cycles</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the objective response rate (complete response [CR] plus unconfirmed complete response [CRu] plus partial response [PR])</outcome>
      <timepoint>baseline to measured progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate progression-free survival</outcome>
      <timepoint>baseline to measured progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>baseline to date of death from any cause</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of overall response</outcome>
      <timepoint>time of response to progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the impact and level of improvement with enzastaurin HCl as it pertains to B symptoms, tumor-related symptoms, patient functioning, quality of life, and overall health status using validated patient questionnaires</outcome>
      <timepoint>baseline, cycle 2, 4 and 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess PKC expression and Ki-67 expression by immunohistochemistry in mantle cell tumors from patients.</outcome>
      <timepoint>baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the safety of enzastaurin HCl in this patient population</outcome>
      <timepoint>each cycle</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the pharmacokinetics of enzastaurin HCl using sparse sampling methodology in this population</outcome>
      <timepoint>cycle 1, 2 and 3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Mantle Cell Lymphoma

          -  Previous treatment for Mantle Cell Lymphoma

          -  Adequate organ function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability to swallow tablets

          -  Must not have had more than 3 prior treatments for Mantle Cell Lymphoma

          -  Must not have significant heart problems</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>61</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Woolloongabba</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Parkville</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Prahran</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Wodonga</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - East Melbourne</hospital>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Wodonga</postcode>
    <postcode> - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg Saar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kassel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purposes of this study are to determine the safety of oral enzastaurin HCl and any side
      effects that might be associated with it and whether enzastaurin HCl can help patients with
      Mantle Cell Lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00088205</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>